(Q28295525)

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

ADHD in adults: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Attention-deficit/hyperactivity disorder in adults: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Stimulant treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Diagnostic controversies in adult attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Methylphenidate effects on symptoms of attention deficit disorder in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Nonstimulant treatment of adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A combined treatment approach for adults with ADHD--results of an open study of 43 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Research forum on psychological treatment of adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Current status of cognitive-behavioral therapy as a psychosocial treatment for adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905

Neuropsychological Studies of Late Onset and Subthreshold Diagnoses of Adult Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2008.09.1905